Development status: Approved, off-patent

Gram-positive activity

Mechanism of Action/Target pathogen: Binds to the peptidyl transferase component of the 50S subunit of the bacterial tRNA complex, thus inhibiting peptide bond formation. It is active against Gram-positive bacteria.

Additional information: Synthetic pleuromutilin derivative for topical use. GSK brands no longer authorised by the European Medicine Agency (EMA) and other agencies.